newsfilter
← Latest News
GlobeNewswire·

Clene Reports First Quarter 2026 Financial Results and Recent Operating Highlights

After successful completion of FDA Type C meeting, Clene expects to submit an NDA for CNM-Au8® under the accelerated approval pathway in the third quarter of 2026In January 2026, Clene completed an oversubscribed